Thursday, January 19, 2023 1:11:02 PM
Ok. But just keep this between us okay? I could get into trouble sharing this insider information.
I am told by my in the know source that Koos is looking to sell the IP to a big pharma for around the same price Kite got from Gilead.
The sticking point is that the big pharma wants P2 data first.
I am told by my in the know source that Koos is looking to sell the IP to a big pharma for around the same price Kite got from Gilead.
The sticking point is that the big pharma wants P2 data first.
FACTS are stubborn things
Recent RGBP News
- Regen BioPharma Update on Orphan Drug Application for HemaXellerate Will Be Presented At Emerging Growth Conference on September 24, 2025 • GlobeNewswire Inc. • 09/23/2025 12:00:00 PM
- Regen BioPharma Prepares Response For FDA Regarding Its Orphan Drug Application for HemaXellerate • GlobeNewswire Inc. • 09/16/2025 12:00:00 PM
